Cargando…
Clinical Pharmacokinetics and Pharmacodynamics of Fostamatinib and Its Active Moiety R406
Fostamatinib is the first approved spleen tyrosine kinase inhibitor for chronic immune thrombocytopenia. This review summarizes the clinical development, pharmacokinetics, pharmacodynamics, drug–drug interactions, adverse events, and comprehensive analyses of fostamatinib. While integrating these fi...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9250994/ https://www.ncbi.nlm.nih.gov/pubmed/35781630 http://dx.doi.org/10.1007/s40262-022-01135-0 |